Gynecologic oncology reports · 2026
Role of anti-Müllerian hormone in predicting premature ovarian insufficiency after pelvic radiotherapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Song Youngju, Jo Yoon Young, Kim Yeon Joo
Аннотация
BACKGROUND AND PURPOSE: Premature ovarian insufficiency (POI) frequently occurs in premenopausal women undergoing pelvic radiotherapy. Anti-Müllerian hormone (AMH) has emerged as a promising biomarker of ovarian reserve, but its role in evaluating post-radiotherapy ovarian function remains uncertain.
MATERIALS AND METHODS: We retrospectively analyzed 23 premenopausal women (≤ 45 years) who received pelvic radiotherapy. POI was defined using two criteria: (1) persistently undetectable AMH (<0.0714 pmol/L) beyond 6 months post-radiotherapy or at last follow-up; and (2) sustained elevation of FSH (>30 mIU/mL) at the same timepoints. Logistic regression was used to identify clinical and dosimetric predictors for POI.
RESULTS: Based on AMH and FSH criteria, POI occurred in nine (39.1%) and eight (34.8%) patients, respectively, with 19 patients showing concordant classifications. AMH declined sharply after radiotherapy, and in some patients, recovered between 6 and 10 months, typically preceding FSH normalization. In AMH-based analysis, sequential brachytherapy following external beam radiotherapy was associated with a higher risk of POI (odds ratio [OR] 55.695, 95% confidence interval [CI] 1.456-2129.833, p = 0.031), and higher minimum radiation dose (Dmin) to the ovary was significantly associated with an increased risk of POI (OR 1.026, 95% CI 1.002-1.051, p = 0.037). For FSH-defined POI, higher ovarian Dmin was also an independent predictor (OR 1.046, 95% CI 1.008-1.086, p = 0.019), indicating a 4.6% increase in the odds of POI per 1 cGy increase in Dmin.
CONCLUSION: In premenopausal women undergoing pelvic radiotherapy, AMH levels declined earlier than FSH and may provide additional information for assessing ovarian reserve. Minimizing ovarian Dmin is important for preserving ovarian function.
MATERIALS AND METHODS: We retrospectively analyzed 23 premenopausal women (≤ 45 years) who received pelvic radiotherapy. POI was defined using two criteria: (1) persistently undetectable AMH (<0.0714 pmol/L) beyond 6 months post-radiotherapy or at last follow-up; and (2) sustained elevation of FSH (>30 mIU/mL) at the same timepoints. Logistic regression was used to identify clinical and dosimetric predictors for POI.
RESULTS: Based on AMH and FSH criteria, POI occurred in nine (39.1%) and eight (34.8%) patients, respectively, with 19 patients showing concordant classifications. AMH declined sharply after radiotherapy, and in some patients, recovered between 6 and 10 months, typically preceding FSH normalization. In AMH-based analysis, sequential brachytherapy following external beam radiotherapy was associated with a higher risk of POI (odds ratio [OR] 55.695, 95% confidence interval [CI] 1.456-2129.833, p = 0.031), and higher minimum radiation dose (Dmin) to the ovary was significantly associated with an increased risk of POI (OR 1.026, 95% CI 1.002-1.051, p = 0.037). For FSH-defined POI, higher ovarian Dmin was also an independent predictor (OR 1.046, 95% CI 1.008-1.086, p = 0.019), indicating a 4.6% increase in the odds of POI per 1 cGy increase in Dmin.
CONCLUSION: In premenopausal women undergoing pelvic radiotherapy, AMH levels declined earlier than FSH and may provide additional information for assessing ovarian reserve. Minimizing ovarian Dmin is important for preserving ovarian function.